Known Safety Data on Lurbinectedin in Pregnancy
Lurbinectedin (brand name Zepzelca) is approved for small cell lung cancer in adults and lacks clinical studies in pregnant or breastfeeding women. Animal data show embryo-fetal toxicity: in rats and rabbits, doses around human equivalents caused resorptions, reduced fetal weight, skeletal variations, and post-implantation loss. No human pregnancy cases are reported in FDA labeling.[1]
Infant Exposure Risks via Breastfeeding
Lurbinectedin is excreted into breast milk in animal models, with radioactivity detected up to 72 hours post-dose. Human data is absent, but its mechanism—binding DNA and inhibiting transcription—suggests potential infant harm. FDA advises against breastfeeding during treatment and for 2 weeks after the last dose.[1]
Limited Evidence on Direct Infant Side Effects
No published studies or post-marketing reports detail specific side effects in infants exposed directly (e.g., via maternal use). Risks mirror chemotherapy-like toxicities: myelosuppression (low blood counts), nausea, fatigue, or developmental delays inferred from class effects (alkylating agents). Pediatric use is unstudied; safety in children under 18 is unknown.[1][2]
Regulatory Warnings and Alternatives
FDA pregnancy category not assigned (uses REMS program); labeled as "may cause fetal harm." Clinicians recommend contraception for patients and partners during treatment plus 4 months after. No infant-specific monitoring guidelines exist due to data gap. For pregnant patients needing therapy, oncology consults weigh benefits vs. risks; alternatives like topotecan may be considered based on case reports.[1][3]
[1]: FDA Zepzelca Label
[2]: Drugs.com Lurbinectedin
[3]: PubMed Pregnancy Outcomes in SCLC